Editorials

Education in Musculoskeletal Health — How Can It Be Improved to Meet Growing Needs?
A.D. Woolf, K. Åkesson ................................................. 455

Curriculum Design: Finding a Balance
L.J. Albert ............................................................................. 458

Rheumatoid Arthritis and Diabetes Mellitus: Evidence for an Association?
M. Doran .............................................................................. 460

Is Minimal Clinically Important Difference Relevant for the Interpretation of Clinical Trials in Pediatric Rheumatic Diseases?
N. Ruperto ............................................................................ 463

Role of Thrombotic and Fibrinolytic Alterations in the Pathogenesis and Treatment of Osteonecrosis
M.A. Mont, S.D. Ulrich, T.M. Seyler ................................. 466

Articles

Prevalent RA and Diabetes Among NHANES III Participants Aged 60 and Older
J.F. Simard, M.A. Mittleman .................................................. 469

Infliximab Does Not Suppress the Tuberculin Skin Test (PPD)
G. Hatemi, M. Melikoglu, I. Fresko, S. Masatioglu, K. Tascilar, H. Yazici ...................................................... 474

Work Disability in RA — Development Over 15 Years and Evaluation of Predictive Factors Over Time
K. Eberhardt, B-M. Larsson, K. Nived, E. Lindqvist .... 481

Hypothesis Adipose Tissue as a Modulator of Clinical Inflammation: Does Obesity Reduce the Prevalence of RA?
T. Bartfai, J. Waalen, J.N. Buxbaum ...................................... 488

Toll-like Receptor Expression in Lupus PBMC
K. Migita, T. Miyashita, Y. Maeda, et al ............................... 493

Outcome Measurements in Scleroderma: Results from a Delphi Exercise
H. Gazi, J.E. Pope, P. Clements, et al ................................ 501

Safety and Efficacy of Readministration of Infliximab After Longterm Continuous Therapy and Withdrawal in Patients with AS
X. Baraliakos, J. Listing, M. Rudwaleit, et al ........................ 510

Low Molecular Weight Phenotype of Apo(a) Is a Risk Factor of Corticosteroid-Induced Osteonecrosis of the Femoral Head After Renal Transplant

Adenoviral Gene Transfer of the Endogenous Inhibitor IkBα into Human OA Synovial Fibroblasts Demonstrates That Several MMP and Aggrecanases Are NF-κB-Dependent
J. Bondeson, S. Lauder, S. Wainwright, et al .................. 523

A Model to Estimate HUI3 Utility Scores from WOMAC Index Scores in Patients with OA of the Knee

Tramadol for OA: A Systematic Review and Metaanalysis
M.S. Cepeda, F. Camargo, C. Zea, L. Valencia .......................... 543

Cyclic Compression Loaded on Cartilage Explants Enhances the Production of ROS

Evaluation of the Activity of an Academic Rheumatology Consult Service Over 10 Years: Using Data to Shape Curriculum
K. Ta, G.C. Gardner ................................................................ 563

Canadian Multidisciplinary Core Curriculum for Musculoskeletal Health

Pediatric Rheumatology

The Quality of My Life Questionnaire: The Minimal Clinically Important Difference for Pediatric Rheumatology Patients
G.W.K. Gong, N.L. Young, H. Dempster, M. Porepa, B.M. Feldman ............................................................... 581

Case Report

Mycophenolate Mofetil and IV Dexamethasone in the Treatment of Persistent Lupus Myelitis
P. Tomietto, S. D’Agostini, V. Annese, S. De Vita, G. Ferraccioli .............................................................................. 588

Rapid Acetabular Osteolysis Secondary to Subchondral Insufficiency Fracture
T. Yamamoto, R. Schneider, Y. Iwamoto, P.G. Bullough ...................................................... 592

Contents continued opposite inside back cover . . .
Images in Rheumatology
Joint Destruction in Septic Arthritis I. Uthman . . . 596

OMERACT 8
International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials, St. Julian’s Bay, Malta, May 10-14, 2006
Introduction M. Boers, V. Strand, L.S. Simon, P. Tugwell, P. Brooks ................................. 599

Biomarkers and Surrogate Endpoints
The WHO International Classification of Functioning, Disability and Health: A Conceptual Model and Interface for the OMERACT Process G. Stucki, A. Boonen, P. Tugwell, A. Cieza, M. Boers ................................. 600
Simulation Studies of Surrogate Endpoint Validation Using Single Trial and Multitrial Statistical Approaches M. Lassere, K. Johnson, M. Hughes, et al ................................. 616

Synovial Macrophages as a Biomarker of Response to Therapeutic Intervention in RA: Standardization and Consistency Across Centers B. Bresnihan, D.M. Gerlag, T. Rooney, et al ................................. 620
Testing of the Preliminary OMERACT Validation Criteria for a Biomarker to Be Regarded as Reflecting Structural Damage Endpoints in RA Clinical Trials: The Example of CRP S.O. Keeling, R. Landewé, D. van der Heijde, et al ................................. 623
Development of Draft Validation Criteria for a Soluble Biomarker to Be Regarded as a Valid Biomarker Reflecting Structural Damage Endpoints in RA and SpA Clinical Trials W.P. Maksymowych, R. Landewé, M. Boers, et al ................................. 634

Letters
Sarcoid-like Granulomatous Disease Following Etanercept Treatment for RA A. Kudrin, E.R. Chilvers, A. Ginawi, et al ................................. 648
CRP in Primary Antiphospholipid Syndrome P.R.J. Ames, C. Tommasino, V. Brancaccio, A. Ciampa ................................. 650
Meetings in Rheumatology .................................